| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
8,559 |
7,780 |
$1.21M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
33,329 |
30,265 |
$961K |
| 93923 |
|
8,532 |
4,211 |
$579K |
| 01992 |
|
10,820 |
8,385 |
$461K |
| 64635 |
|
2,427 |
1,871 |
$239K |
| 95924 |
|
4,488 |
4,148 |
$230K |
| 64636 |
|
2,364 |
1,790 |
$183K |
| 64493 |
|
2,099 |
1,630 |
$143K |
| 80305 |
|
19,313 |
17,364 |
$139K |
| 95923 |
|
3,694 |
3,431 |
$117K |
| 62323 |
|
847 |
664 |
$96K |
| 80346 |
|
3,889 |
3,538 |
$73K |
| 64494 |
|
2,293 |
1,519 |
$70K |
| 27096 |
|
427 |
346 |
$64K |
| 64495 |
|
2,228 |
1,467 |
$59K |
| 80362 |
|
7,622 |
3,538 |
$51K |
| 80361 |
|
3,889 |
3,538 |
$50K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
1,233 |
1,137 |
$49K |
| 99454 |
|
1,392 |
1,336 |
$45K |
| 80320 |
|
3,889 |
3,538 |
$41K |
| 80368 |
|
3,889 |
3,538 |
$40K |
| 83992 |
|
3,893 |
3,541 |
$40K |
| 99457 |
|
1,385 |
1,334 |
$35K |
| 80360 |
|
3,889 |
3,538 |
$35K |
| 80345 |
|
3,889 |
3,538 |
$35K |
| 80324 |
|
3,889 |
3,538 |
$35K |
| 90832 |
Psychotherapy, 30 minutes with patient |
1,038 |
829 |
$34K |
| 80366 |
|
3,889 |
3,538 |
$33K |
| 80355 |
|
3,889 |
3,538 |
$33K |
| 80367 |
|
3,889 |
3,538 |
$33K |
| 80333 |
|
3,889 |
3,538 |
$33K |
| 80337 |
|
3,888 |
3,538 |
$33K |
| 80372 |
|
3,889 |
3,538 |
$33K |
| 80373 |
|
3,938 |
3,538 |
$33K |
| 80369 |
|
3,889 |
3,538 |
$33K |
| 80323 |
|
3,889 |
3,538 |
$31K |
| 80354 |
|
3,889 |
3,538 |
$28K |
| 80365 |
|
3,889 |
3,538 |
$28K |
| 80356 |
|
3,889 |
3,538 |
$28K |
| 80348 |
|
3,889 |
3,538 |
$28K |
| 80371 |
|
3,889 |
3,538 |
$28K |
| 80353 |
|
3,889 |
3,538 |
$28K |
| 80359 |
|
3,906 |
3,538 |
$28K |
| 80350 |
|
3,889 |
3,538 |
$28K |
| 80349 |
|
3,861 |
3,511 |
$28K |
| 80358 |
|
3,853 |
3,503 |
$28K |
| G0483 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed |
3,411 |
3,111 |
$24K |
| J1040 |
Injection, methylprednisolone acetate, 80 mg |
3,477 |
2,732 |
$23K |
| 77002 |
|
1,532 |
1,151 |
$23K |
| 93040 |
|
4,430 |
4,131 |
$20K |
| 64490 |
|
224 |
183 |
$16K |
| 99401 |
|
1,400 |
1,311 |
$14K |
| J1030 |
Injection, methylprednisolone acetate, 40 mg |
2,573 |
1,973 |
$10K |
| 64491 |
|
247 |
183 |
$8K |
| 64483 |
|
109 |
89 |
$8K |
| J2704 |
Injection, propofol, 10 mg |
9,736 |
7,510 |
$6K |
| 64484 |
|
97 |
77 |
$6K |
| 64492 |
|
199 |
141 |
$5K |
| 64633 |
|
53 |
34 |
$5K |
| 01940 |
|
134 |
102 |
$5K |
| 64634 |
|
52 |
34 |
$5K |
| 64450 |
|
117 |
83 |
$5K |
| 96521 |
|
55 |
13 |
$4K |
| 77003 |
|
1,075 |
831 |
$3K |
| J1010 |
Injection, methylprednisolone acetate, 1 mg |
884 |
711 |
$3K |
| J3490 |
Unclassified drugs |
973 |
756 |
$3K |
| 99406 |
|
558 |
512 |
$2K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
55 |
13 |
$2K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
279 |
269 |
$2K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
32 |
32 |
$1K |
| 64445 |
|
17 |
12 |
$1K |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
5,829 |
4,678 |
$1K |
| 99453 |
|
120 |
113 |
$1K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
55 |
13 |
$974.96 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
6,089 |
4,640 |
$857.31 |
| 80306 |
|
365 |
347 |
$749.64 |
| 99072 |
|
7,841 |
6,393 |
$526.13 |
| 99497 |
|
346 |
322 |
$496.32 |
| 01991 |
|
23 |
13 |
$415.35 |
| 36415 |
Collection of venous blood by venipuncture |
55 |
13 |
$233.37 |
| A4209 |
Syringe with needle, sterile 5 cc or greater, each |
2,170 |
1,642 |
$183.16 |
| 82962 |
|
55 |
13 |
$178.70 |
| 94060 |
|
14 |
14 |
$131.84 |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
69 |
64 |
$75.10 |
| A4649 |
Surgical supply; miscellaneous |
1,562 |
1,186 |
$56.96 |
| A4208 |
Syringe with needle, sterile 3 cc, each |
1,499 |
1,126 |
$49.43 |
| J0665 |
Injection, bupivicaine, not otherwise specified, 0.5 mg |
412 |
330 |
$43.17 |
| 94760 |
|
4,008 |
3,787 |
$30.63 |
| J1817 |
Insulin for administration through dme (i.e., insulin pump) per 50 units |
55 |
13 |
$19.76 |
| J7050 |
Infusion, normal saline solution, 250 cc |
24 |
16 |
$7.59 |
| G0444 |
Annual depression screening, 5 to 15 minutes |
303 |
282 |
$0.76 |
| G8482 |
Influenza immunization administered or previously received |
2,371 |
1,952 |
$0.00 |
| 4040F |
|
3,575 |
3,257 |
$0.00 |
| G8783 |
Normal blood pressure reading documented, follow-up not required |
1,033 |
946 |
$0.00 |
| 4004F |
|
1,860 |
1,705 |
$0.00 |
| G9744 |
Patient not eligible due to active diagnosis of hypertension |
1,381 |
1,259 |
$0.00 |
| G8753 |
Most recent systolic blood pressure >= 140 mmhg |
1,682 |
1,527 |
$0.00 |
| 99408 |
|
102 |
96 |
$0.00 |
| G8417 |
Bmi is documented above normal parameters and a follow-up plan is documented |
2,820 |
2,575 |
$0.00 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
3,264 |
2,992 |
$0.00 |
| G0446 |
Annual, face-to-face intensive behavioral therapy for cardiovascular disease, individual, 15 minutes |
279 |
246 |
$0.00 |
| G8752 |
Most recent systolic blood pressure < 140 mmhg |
1,642 |
1,496 |
$0.00 |
| G8484 |
Influenza immunization was not administered, reason not given |
1,001 |
866 |
$0.00 |
| G0247 |
Routine foot care by a physician of a diabetic patient with diabetic sensory neuropathy resulting in a loss of protective sensation (lops) to include, the local care of superficial wounds (i.e. superficial to muscle and fascia) and at least the following if present: (1) local care of superficial wounds, (2) debridement of corns and calluses, and (3) trimming and debridement of nails |
173 |
145 |
$0.00 |
| G8754 |
Most recent diastolic blood pressure < 90 mmhg |
1,882 |
1,713 |
$0.00 |
| G8755 |
Most recent diastolic blood pressure >= 90 mmhg |
1,379 |
1,250 |
$0.00 |
| G8420 |
Bmi is documented within normal parameters and no follow-up plan is required |
212 |
186 |
$0.00 |
| G8950 |
Elevated or hypertensive blood pressure reading documented, and the indicated follow-up is documented |
879 |
780 |
$0.00 |
| 1036F |
|
1,495 |
1,348 |
$0.00 |
| G0245 |
Initial physician evaluation and management of a diabetic patient with diabetic sensory neuropathy resulting in a loss of protective sensation (lops) which must include: (1) the diagnosis of lops, (2) a patient history, (3) a physical examination that consists of at least the following elements: (a) visual inspection of the forefoot, hindfoot and toe web spaces, (b) evaluation of a protective sensation, (c) evaluation of foot structure and biomechanics, (d) evaluation of vascular status and skin integrity, and (e) evaluation and recommendation of footwear and (4) patient education |
172 |
144 |
$0.00 |